About Txinno
Txinno is a company based in Yongin (South Korea) founded in 2020 by Chan-Sun Park and Seongjun Kim. Txinno has raised $5.95 million across 1 funding round from investors including Korea Investment Holdings, DSC Investment and Company K Partners. Txinno offers products and services including Drug Development Platform and Pipeline Services. Txinno operates in a competitive market with competitors including BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
- Headquarter Yongin, South Korea
- Founders Chan-Sun Park, Seongjun Kim
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name (주)티씨노바이오사이언스
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$5.95 M (USD)
in 1 rounds
-
Latest Funding Round
$5.95 M (USD), Series A
Aug 20, 2021
-
Investors
Korea Investment Holdings
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Txinno
Txinno offers a comprehensive portfolio of products and services, including Drug Development Platform and Pipeline Services.
Platform for developing small molecule anticancer drugs
Services for innovative drug pipelines in cancer treatment
Funding Insights of Txinno
Txinno has successfully raised a total of $5.95M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.95 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $5.9M
-
First Round
First Round
(20 Aug 2021)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2021 | Amount | Series A - Txinno | Valuation | Company K Partners , DSC Investment |
|
Investors in Txinno
Txinno has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Korea Investment Holdings, DSC Investment and Company K Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in tech startups
|
Founded Year | Domain | Location | |
|
Early-stage venture capital is invested primarily in South Korean startups.
|
Founded Year | Domain | Location | |
|
Investment holding firm established in Seoul in 2003.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Txinno
Financial Statements - Txinno
Txinno Comparisons
Competitors of Txinno
Txinno operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
mRNA therapeutics platform is provided for multi-functional treatments.
|
Latest news on Txinno
Frequently Asked Questions about Txinno
Txinno was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Txinno is headquartered in Yongin, South Korea. It is registered at Yongin, Gyeonggi, South Korea.
Chan-Sun Park is the current CEO of Txinno. They have also founded this company.
Txinno is a funded company, having raised a total of $5.95M across 1 funding round to date. The company's 1st funding round was a Series A of $5.95M, raised on Aug 20, 2021.
Developer of therapeutics for the treatment of cancer. The company develops therapeutic agents focusing on the two characteristics, small-molecule compound targeting innate immunity in immunotherapy and RAS mutated anti-cancer drug in targeted cancer therapy.
Txinno's top competitors include Moderna, BeiGene and Strand Therapeutics.
Txinno offers Drug Development Platform and Pipeline Services.
Txinno has 4 investors. Key investors include Korea Investment Holdings, DSC Investment, Company K Partners, and Schmidt.